Clinical Trial Update: Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of a PD-1 antibody in combination with a histone deacetylase inhibitor for advanced cervical cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Anti-PD-1 antibody
• histone deacetylase inhibitor

Snippet

Sponsor: Sun Yat-sen University | Conditions: Cervical Cancer, Cervix Cancer | Phase 1, Phase 2 | Status: TERMINATED